4.6 Article

APASL consensus statements and recommendation on treatment of hepatitis C

Journal

HEPATOLOGY INTERNATIONAL
Volume 10, Issue 5, Pages 702-726

Publisher

SPRINGER
DOI: 10.1007/s12072-016-9717-6

Keywords

APASL; DAAs; HCV; Interferon-free; Turkey

Funding

  1. Bayer Co
  2. Boehringer Ingelheim
  3. Bristol-Myers Squibb
  4. Otsuka
  5. Astellas
  6. Gilead Sciences
  7. Chugai
  8. Mitsubishi Tanabe
  9. Kyorin
  10. Merck Sharp Dohme
  11. Dainippon Sumitomo
  12. Vertex Pharmaceuticals
  13. Takeda
  14. Zeria
  15. Chugai Pharmaceutical
  16. MSD
  17. Tanabe-Mitsubishi
  18. Daiichi-Sankyo
  19. Abbvie
  20. Roche
  21. Abbott
  22. BMS
  23. Gilead
  24. Kowa Souku
  25. Sysmex
  26. Chugai Pharmaceutical Co
  27. GlaxoSmithKline
  28. Ajinomoto-Seiyaku
  29. Bayer
  30. Given Imaging
  31. Mitsubishi Tanabe Pharm
  32. Taiho Yakuhin
  33. Dainippon Sumitomo Pharm
  34. Igaku-Seibutsugaku Institute

Ask authors/readers for more resources

The Asian-Pacific Association for the Study of the Liver (APASL) convened an international working party on the APASL consensus statements and recommendation on management of hepatitis C in March, 2015, in order to revise APASL consensus statements and management algorithms for hepatitis C virus infection (Hepatol Int 6:409-435, 2012). The working party consisted of expert hepatologists from the Asian-Pacific region gathered at Istanbul Congress Center, Istanbul, Turkey on 13 March 2015. New data were presented, discussed and debated to draft a revision. Participants of the consensus meeting assessed the quality of cited studies. Finalized recommendations on treatment of hepatitis C are presented in this review.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available